{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:22:29Z","timestamp":1788013349826,"version":"build-2784847793"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA142509"],"award-info":[{"award-number":["P50CA142509"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["SCOR-12206-17"],"award-info":[{"award-number":["SCOR-12206-17"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-026-01489-9","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:23:30Z","timestamp":1776068610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7218-9960","authenticated-orcid":false,"given":"Christen M.","family":"Dillard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Kalariya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9193-0059","authenticated-orcid":false,"given":"Oren","family":"Pasvolsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2997-4856","authenticated-orcid":false,"given":"Christopher","family":"Ferreri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3928-6590","authenticated-orcid":false,"given":"Mahmoud","family":"Gaballa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8596-7058","authenticated-orcid":false,"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Becnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2876-2886","authenticated-orcid":false,"given":"Muzaffar","family":"Qazilbash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5723-4129","authenticated-orcid":false,"given":"Robert Z.","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A. T.","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8894-027X","authenticated-orcid":false,"given":"Krina K.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"1489_CR1","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2023;388:1002\u201314.","journal-title":"N Engl J Med"},{"key":"1489_CR2","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"J San-Miguel","year":"2023","unstructured":"San-Miguel J, Dhakal B, Yong K, Spencer A, Anguille S, Mateos M-V, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023;389:335\u201347.","journal-title":"N Engl J Med"},{"key":"1489_CR3","first-page":"4352","volume":"130","author":"V Bhatnagar","year":"2017","unstructured":"Bhatnagar V, Gormley N, Kazandjian D, Goldberg K, McKee AE, Blumenthal G, et al. FDA analysis of racial demographics in multiple myeloma trials. Blood. 2017;130:4352.","journal-title":"Blood"},{"key":"1489_CR4","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","volume":"3","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi S, Parikh K, Abouzaid S, Zhou Z, Tang W, Clancy Z, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A SEER-Medicare analysis. Blood Adv. 2019;3:2986\u201394.","journal-title":"Blood Adv"},{"key":"1489_CR5","doi-asserted-by":"publisher","first-page":"S322","DOI":"10.1016\/j.jtct.2023.12.446","volume":"30","author":"KK Patel","year":"2024","unstructured":"Patel KK, Rodr\u00edguez-Otero P, Nooka AK, Callander NS, Solomon SR, Baz R, et al. Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in Triple-Class\u2013Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3 Subanalysis of Black Patients (pts). Transplant Cell Ther. 2024;30:S322.","journal-title":"Transplant Cell Ther"},{"key":"1489_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/bloodadvances.2023010894","volume":"8","author":"LC Peres","year":"2024","unstructured":"Peres LC, Oswald LB, Dillard CM, De Avila G, Nishihori T, Blue BJ, et al. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy. Blood Adv. 2024;8:251\u20139.","journal-title":"Blood Adv"},{"key":"1489_CR7","doi-asserted-by":"publisher","first-page":"e0001060","DOI":"10.1371\/journal.pgph.0001060","volume":"2","author":"C Lu","year":"2022","unstructured":"Lu C, Ahmed R, Lamri A, Anand SS. Use of race, ethnicity, and ancestry data in health research. PLOS Glob Public Health. 2022;2:e0001060.","journal-title":"PLOS Glob Public Health"},{"key":"1489_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-246","volume":"12","author":"DH Alexander","year":"2011","unstructured":"Alexander DH, Lange K. Enhancements to the ADMIXTURE algorithm for individual ancestry estimation. BMC Bioinformatics. 2011;12:246.","journal-title":"BMC Bioinformatics"},{"key":"1489_CR9","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"1489_CR10","doi-asserted-by":"publisher","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Y Lin","year":"2024","unstructured":"Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B, et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. Lancet Oncol. 2024;25:e374\u201387.","journal-title":"Lancet Oncol"},{"key":"1489_CR11","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","volume":"6","author":"S Kambhampati","year":"2022","unstructured":"Kambhampati S, Sheng Y, Huang CY, Bylsma S, Lo M, Kennedy V, et al. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Blood Adv. 2022;6:2045.","journal-title":"Blood Adv"},{"key":"1489_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.09.025","volume":"167","author":"Y N\u00e9d\u00e9lec","year":"2016","unstructured":"N\u00e9d\u00e9lec Y, Sanz J, Baharian G, Szpiech ZA, Pacis A, Dumaine A, et al. Genetic Ancestry and Natural Selection Drive Population Differences in Immune Responses to Pathogens. Cell. 2016;167:657\u201369.e21.","journal-title":"Cell"},{"key":"1489_CR13","doi-asserted-by":"publisher","first-page":"5479","DOI":"10.1182\/bloodadvances.2023012522","volume":"8","author":"ML Palacios-Berraquero","year":"2024","unstructured":"Palacios-Berraquero ML, Rodriguez-Marquez P, Calleja-Cervantes ME, Berastegui N, Zabaleta A, Burgos L, et al. Molecular mechanisms promoting long-term cytopenia after BCMA CAR-T therapy in multiple myeloma. Blood Adv. 2024;8:5479\u201392.","journal-title":"Blood Adv"},{"key":"1489_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","volume":"16","author":"K Rejeski","year":"2023","unstructured":"Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.","journal-title":"J Hematol Oncol"},{"key":"1489_CR15","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_433520","volume":"44","author":"MJ Rees","year":"2024","unstructured":"Rees MJ, D\u2019Agostino M, Leypoldt LB, Kumar S, Weisel KC, Gay F. Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies. Am Soc Clin Oncol Educ Book. 2024;44:e433520.","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01489-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01489-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T08:23:31Z","timestamp":1776068611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-026-01489-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1489"],"URL":"https:\/\/doi.org\/10.1038\/s41408-026-01489-9","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CMD: Nothing to disclose. HCL: Research funding paid to institution: Amgen, Bristol Myers Squibb, Janssen, GlaxoSmithKline, Regeneron, Takeda Pharmaceuticals, Alexion, Menarini, AstraZeneca, Moderna. Consulting fees paid to institution: Bristol Myers Squibb, Janssen, GlaxoSmithKline, Takeda Pharmaceuticals, Pfizer. Consulting fees paid to self: Bristol Myers Squibb, Alexion Pharmaceuticals, Janssen, Regeneron, GlaxoSmithKline, Sanofi, Takeda Pharmaceuticals, Pfizer, Menarini. Data Safety and Monitoring Board: Allogene Therapeutics, Takeda Pharmaceuticals. NK: Nothing to disclose. NS: Nothing to disclose. OP: Nothing to disclose. CF: Nothing to disclose. MG: Nothing to disclose. SKT: Consulting: Abbvie, Cellectar Biosciences, Mustang Bio. Research Funding: Abbvie, Ascentage Pharma, Acerta Pharma, Bristol Myers Squibb, Cellectar Biosciences, Genentech, Janssen, Sanofi, X4 Pharma. DMW: Nothing to disclose. MB: Nothing to disclose. GK: Nothing to disclose. MHQ: Research Funding: Amgen, Angiocrine Bioscience, BioLineRx, Janssen Pharmaceuticals, NexImmune. RZO: He is a founder of Asylia Therapeutics and has an equity interest. Advisory Boards: Amgen, Bristol Myers Squibb, Celgene, EcoR1 Capital, Forma Therapeutics, Genzyme, GSK Biologicals, Ionis Pharmaceuticals, Janssen Biotech, Juno Therapeutics, Kite Pharma, Legend Biotech, Molecular Partners, Sanofi, Servier, Takeda Pharmaceuticals North America. Research Funding: Asylia Therapeutics, Biotheryx, and Heidelberg Pharma AG. MATH: Nothing to disclose. KKP: Consulting: Abbvie, AstraZeneca, Bristol Myers Squibb, Caribou Sciences, Johnson & Johnson (Janssen), Genentech, Kite, Legend biotech, Merck, Novartis, Pfizer, Oricel, Sanofi, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board (IRB) of The University of Texas MD Anderson Cancer Center (Protocol # 2022-0042). As this study was a retrospective record review, the requirement for informed consent was waived. The study involves no prospectively collected data, and the research poses minimal risk to subjects. All data was de-identified prior to analysis to ensure patient confidentiality.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"59"}}